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Abstract
Steroid-related cancers can be treated by inhibitors of steroid metabolism. In searching for new inhibitors of human 17beta-
hydroxysteroid dehydrogenase type 1 (17b-HSD 1) for the treatment of breast cancer or endometriosis, novel substances
based on 15-substituted estrone were validated. We checked the specificity for different 17b-HSD types and species.
Compounds were tested for specificity in vitro not only towards recombinant human 17b-HSD types 1, 2, 4, 5 and 7 but also
against 17b-HSD 1 of several other species including marmoset, pig, mouse, and rat. The latter are used in the processes of
pharmacophore screening. We present the quantification of inhibitor preferences between human and animal models.
Profound differences in the susceptibility to inhibition of steroid conversion among all 17b-HSDs analyzed were observed.
Especially, the rodent 17b-HSDs 1 were significantly less sensitive to inhibition compared to the human ortholog, while the
most similar inhibition pattern to the human 17b-HSD 1 was obtained with the marmoset enzyme. Molecular docking
experiments predicted estrone as the most potent inhibitor. The best performing compound in enzymatic assays was also
highly ranked by docking scoring for the human enzyme. However, species-specific prediction of inhibitor performance by
molecular docking was not possible. We show that experiments with good candidate compounds would out-select them in
the rodent model during preclinical optimization steps. Potentially active human-relevant drugs, therefore, would no longer
be further developed. Activity and efficacy screens in heterologous species systems must be evaluated with caution.
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Introduction
Human diseases could be treated by selective manipulation of
pathways involved in their pathogenesis. Several druggable targets
were defined in humans [1,2] including steroid metabolizing
enzymes like 17b-hydroxysteroid dehydrogenases (17b-HSDs)
controlling the biological potency of steroid hormones by redox
reactions at position 17 of the steroid scaffold [3,4,5,6,7]. 17b-
HSDs belong to the short-chain dehydrogenase/reductase super-
family (SDR) [8], except for 17b-HSD type 5 which is a member
of aldoketoreductase (AKR) superfamily [9].
Since the observation of the prognostic value of 17b-HSDs in
breast or prostate cancers [10,11,12,13,14] the research on these
enzymes included development of specific inhibitors
[15,16,17,18,19,20,21,22,23]. It was assumed that in hormone-
dependent cancers an inhibitor of conversion of estrone to
estradiol by 17b-HSD 1 would deplete the biologically active
hormone estradiol from the signal transduction pathway and by
that constrain cell proliferation in breast cancer or endometriosis.
Therefore, extensive strategies included 17b-HSD 1 as a drug
target [21,22]. We recently contributed to this field by a
development of novel effective inhibitors of this enzyme by
exploring modifications at positions 2 or 15 of estrone (compounds
1, 2 and 3 in this study) [24] and designing fluorine derivatives of
estrone [25].
The growing number of genetically and functionally distinct
17b-HSDs makes it difficult to develop enzyme-specific inhibitors.
At least fourteen types of 17b-HSDs are known so far with partly
overlapping or reciprocal substrate preferences and not always
distinct tissue distribution [5,6,7,26,27]. Furthermore, specificity
analyses are affected by the nature of assay systems like in vitro
assays with recombinant protein or ex vivo measurements in cell
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inhibition results seen for human 17b-HSDs in animal models,
mostly rodents, has to cope with the problem of differences to
humans in sex steroid metabolism [28,29,30,31].
In this work we focused on the inhibition of 17b-HSDs
converting estrogens and androgens. We analyzed (i) how
susceptible human 17b-HSD 1, 2, 4, 5 and 7 were to inhibition
by a novel class of 15-substituted estrogens described in our
patents [24], and (ii) how the candidate inhibitors were modulating
the activity of 17b-HSD 1 from different species including human,
marmoset, pig, mouse and rat. Because profound differences
between the orthologs in the susceptibility to inhibition were
observed, we also analyzed (iii) if molecular docking experiments
performed with modeled enzymes can differentiate or predict the
efficacy of inhibitors.
Results
Validation of 17b-HSD Type Specificity
Several types of 17b-HSDs were chosen to check the specificity
of recently developed inhibitors [24] against human 17b-HSD 1.
Structure-function relationships were already reported for these
inhibitors [24] and will not be analyzed in this manuscript. We
monitored the inhibition at the physiological preferences of the
17b-HSDs, i.e. reduction of estrone to 17b-estradiol by 17b-HSD
1 and 7, the reduction of androstenedione to testosterone by 17b-
HSD 5, and the oxidation of 17b-estradiol to estrone by types 2
and 4. We restricted our assay to this set of enzymes as they are
active after recombinant expression in bacteria and could be used
for fast, robust and inexpensive screens of inhibitors. Other 17b-
HSD types require transfection into mammalian cell lines for
activity assays (type 3 or 14, [32,33]) or were excluded for being
physiologically irrelevant to this study (type 12 [34]).
With this set of recombinant enzymes we have checked the
relative inhibition of different reaction directions by 15-substituted
estrogens [24] and a 16b-substituted estrogen [35] (for structures
see Figure 1). We observed that compounds number 2 and 3
revealed high inhibition of the human 17b-HSD 1 reductive
activity with very low inhibition of the other human 17b-HSDs
(Figure 2). The substances reached a better selectivity than the
Sterix reference compound 5 [35] especially showing less influence
on 17b-HSD 5. However, as illustrated by measurements of our
other compounds, not all substitutions at position 15 are very
selective. For example substance 4 inhibits 17b-HSD 5 to the same
amount as human 17b-HSD 1.
Analysis of Inhibitor Influence on Activity of 17b-HSD 1 in
Different Species
We have included all inhibitors in the next testing of
susceptibility to inhibition of 17b-HSD 1 in different species. We
prepared a set of recombinant 17b-HSDs 1 originating from
human, marmoset, pig, mouse and rat. These 17b-HSD 1
enzymes reveal high level of amino acid similarity (Figure 3)
ranging from 85% for human-marmoset to 78% for human-rat
pairwise comparisons. The most divergent residues of the
sequences are located in their C-terminal parts.
Clear differences in the inhibitor influence on activity of 17b-
HSD 1 of different species were observed (Figure 4). Surprisingly,
the rodent enzymes revealed the biggest discrepancies to values
measured for the human enzymes with all inhibitors. Comparable
inhibition efficacy to that of human 17b-HSD 1 was observed for
the marmoset and pig enzymes. To facilitate normalization and
direct comparison with published records we included estrone
(compound 6) to our study. The estrone was used because it is a
natural ligand of 17b-HSD 1 and because it causes substrate
inhibition in higher concentrations by a formation of dead-end
complex [37]. The estrone turned out to be a potent inhibitor of
all tested 17b-HSD 1 orthologs.
We further checked the inhibition of the best inhibitors, the
compounds 2 and 3,b yI C 50 determination (Table 1). These data
allowed quantification of efficacy of inhibition between 17b-HSDs
1 of different species. Pig 17b-HSD 1 is affected by both inhibitors
in nearly the same concentration range as the human enzyme.
Marmoset monkey 17b-HSD 1 requires a higher concentration to
be blocked. The rodent enzymes were inhibited only up to 10 and
40% by compounds 2 and 3, respectively. This precluded IC50
determination for the rodent enzymes.
Validation of Candidate Compounds by Molecular
Docking
Although the overall amino acid sequences of 17b-HSD 1 are
very similar in different species (Figure 3) some differences are
present. These differences lead to structural changes in enzyme
substrate binding pocket and therefore add to differences in the
potency of inhibitors in the different enzymes. We checked if
molecular docking experiments can contribute to the challenge of
prediction of inhibitor specificity. Molecular docking is a valuable
approach in the analyses of ligand-protein interaction and can be
used for pre-selection of pharmacophores as candidates for
enzyme inhibitors. To accomplish that we performed docking of
inhibitors to models of the different 17b-HSDs that were also
enzymatically tested in this study. Please note that the docking
experiments were performed only including most similar parts of
enzymes, i.e. taking the amino acid sequence from the N-terminus
up to the position marked by an arrow as shown in the Figure 3.
The divergent C-terminal parts of proteins were neither used in
modeling nor docking studies.
We first performed a global comparison of all enzyme types in
all species with known in vitro inhibition data. Results of the first
round of docking experiments are depicted in the Supporting
Information (Table S1). Experimental inhibition effects were
available for 49 protein-compound pairs. The absolute correlation
between scores predicted by 7 docking programs and measured
inhibition ranged between 1% and 36% (AutoDock: 36%, eHits:
26%, Cdocker: 19%, SurFlex: 16%, Dock: 12%, LigFit: 9%,
Glide: 1%). Higher docking scores correspond to higher fitting of
compounds into the protein structures.
We realized that the correlation in this set of protein-compound
pairs should not be used to judge the quality of the docking
programs. This is because the correlation varies a lot due to
flexibility of both the protein and the compound. However, when
applying a consensus mode instead of individual approaches an
assessment of 17b-HSD inhibitors can be gained. When exploring
a consensus of the docking methods we observed a correlation of
57%. However, when the jackknife procedure for elimination of
training (memorization) effects was employed the correlation
coefficient dropped to 32%, which is lower than the best
performing method on this set (AutoDock: 36%). A modified
consensus method that utilizes only 2 docking programs (Auto-
Dock & eHits) exhibited an improved correlation to 41%, which
was better than any single docking method in the set. Only this
final method was used for subsequent data analyses. The relation
between all predicted and measured inhibition values is visualized
in Figure 5.
Next we analyzed data from 17b-HSDs 1 of different species.
For human and marmoset data there is a good correlation
between the predicted ranking of compounds as inhibitors by
molecular docking scores and measured inhibition efficacy
Species-Dependent Inhibition
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e10969Figure 1. Structures of compounds used in the study. a Sterix compound, b product of estradiol oxidation.
doi:10.1371/journal.pone.0010969.g001
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PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e10969Figure 2. Analysis of inhibitor specificity among different human 17b-HSD types. Negative values correspond to a weak activation. All
assays were run in duplicates of two independent experiments, normalized to control assay and reported as mean values 6 SEM. Inhibitors were
tested at 2 mM final concentration. Structures are shown in Figure 1. For referencing purposes the traditional and new names [8] of different human
17b-hydroxysteroid dehydrogenase types are given: 17b-HSD 1 – SDR28C1, 17b-HSD 2 – SDR9C2, 17b-HSD 4 – SDR8C1, 17b-HSD 5 – AKR1C3, 17b-
HSD 7 – SDR37C1.
doi:10.1371/journal.pone.0010969.g002
Figure 3. Amino acid sequence comparison of 17b-HSDs 1 of different species. Species are given to the left, followed by amino acid
residue numbering. Identical amino acid residues are given white on black, whereas similar residues are grey shaded. Arrow points to the last C-
terminal amino acid resolved in the crystal structure of PDB entry 1A27.
doi:10.1371/journal.pone.0010969.g003
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susceptibility to inhibitors and their measured inhibition values
reveal less correlation with the corresponding docking scores. For
all 5 species models of the 17b-HSD 1 enzymes the consensus
method predicted estrone (compound 6) as the most potent
inhibitor (best fitting compound) in agreement with the experi-
mental data (Figure 4 and Table 2). On the average, estrone is the
best natural inhibitor for all species studied.
We further analyzed the predictive value of molecular docking
for different human 17b-HSD types. This docking approach
ranked compounds 1 and 2 as best in silico hits. However, the
measured inhibition ranks compounds 2, 3 and 1 as most specific
inhibitors of human 17b-HSDs 1. This observation is based on the
lowest inhibition for the human 17b-HSD 2, 4, 5, and 7 at highest
inhibition of 17b-HSDs 1 (Table 3).
Discussion
Rationale for Inhibitor Search
The development of therapies for estrogen-dependent human
diseases addresses the pre-receptor metabolism [38,39,40], which
includes inhibition of enzymes like steroid sulfatase (STS), P450
aromatase and 17b-HSD 1. The design and application of STS
inhibitors [41,42], aromatase inhibitors [43,44,45], and combined
STS-aromatase inhibitors [46] are showing significant therapeutic
promise. On the other hand, the inhibitors for human 17b-HSD 1
are still at an early stage of development [34,47,48,49] and have
not reached clinical studies yet. Nevertheless, many efforts were
undertaken in the finding effective inhibitors for human 17b-HSD
1 [21]. Selective 17b-HSD 1 inhibitors were reported with
modifications of the steroid scaffold at positions 6, 16 or 17
[16,18,19,50,51,52], substitution with sulfamates [53,54], ben-
zenes [55] or fluorine [25], in form of hybrid inhibitors constituted
of estradiol with adenosine [17,56,57] and non-steroidal com-
pounds [58,59,60]. Their activities are already reaching effective
and selective inhibition of the human 17b-HSD 1 with
pharmacologically attractive IC50 values in the nanomolar range.
Our recent patents on 15-substituted estrone [24,61] contributed
to a new direction to this research.
Challenge of Animal Models
Although animal models found broad applications in drug
discovery they are not ideal phenocopies of human physiology in
health and disease. Both enzyme expression levels and amino acid
compositions of homologous enzymes are not the same. Conse-
quently substrate preferences of steroid metabolizing enzymes in
humans and other mammalian species are different for estrogens,
androgens and glucocorticoids [7,29] and in turn drug susceptibility is
expected also to be different. Recently, inhibitors of glucocorticoid
metabolism were shown to effect orthologs of different mammalian
species [62] to various extent. Similar experiments including several
species at the same time were not yet performed. Only one
publication addressed the inhibitory potency of putative drugs
against estrogenic 17b-HSDs in rats [31].
Our results now prove that the estrogenic 17b-HSDs 1 from
different species indeed are distinctly affected by inhibitory
compounds. Especially the lack of inhibition of the rodent
enzymes by the most potent inhibitors of human 17b-HSD 1 is
to be underlined. This is not very surprising since it is well known
Figure 4. Inhibitors of activity of 17b-HSD 1 of different species. Different inhibitors were tested. Estrone (compound 6) was included to
check the inhibition by the native substrate. Negative values correspond to a weak activation. All assays were run in duplicates of two independent
experiments, normalized to control assay and mean values 6 SEM reported. Inhibitors were tested at 2 mM final concentration. For structures see
Figure 1.
doi:10.1371/journal.pone.0010969.g004
Table 1. Comparison of IC50 values obtained for inhibition of
17b-HSDs 1 in different species.
Compound
number IC50
Human Marmoset Pig Mouse Rat
2 87.4 nM 3607 uM 457 nM nd nd
3 1.3 nM 95.3 nM 0.34 nM nd nd
nd - not to determine, due to too low inhibition.
doi:10.1371/journal.pone.0010969.t001
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[28,29,30]. However, we provide a ranking of inhibitor efficacy for
enzymes in different species. In case of preclinical animal tests,
which are usually performed in mouse or rat, the most potent
inhibitory compounds would have been sorted out before entering
further development for human application.
Lessons from Docking Experiments
Several novel potential inhibitors for 17b-hydroxysteroid
dehydrogenases have been docked using available algorithms but
applying a novel set of auxiliary simulation scripts. Although
scoring accuracy and range of applications of computational
docking has improved in the last years, resulting partially from
Figure 5. Relation between the predicted and observed inhibition values. Results are given for a modified consensus method that utilizes
only two docking programs AutoDock and eHits.
doi:10.1371/journal.pone.0010969.g005
Table 2. Comparison of predicted and measured inhibition for 17b-HSD 1 orthologs of five species.
Predicted consensus score
Species Compound
123456
Human 72.1 53.6 53.6 57.1 58.1 101.3
Marmoset 38.1 45.2 52.5 58.5 35.7 78.1
Mouse 39.2 21.3 22.4 57.1 15.8 94.3
Pig n.m. 21.5 24.0 35.0 35.3 74.6
Rat 32.9 32.3 30.9 54.8 27.8 86.7
average: 45.6 30.2 36.7 52.5 34.5 87.0
Observed % inhibition
Species Compound
123456
Human 63.6 94.7 97.9 95.8 100.0 100.6
Marmoset 30.6 60.3 98.5 85.2 45.6 109.5
Mouse 27.0 21.5 27.0 18.5 3.2 101.4
Pig n.m. 67.0 104.7 66.2 95.7 86.3
Rat 47.1 40.3 5.3 19.4 22.4 79.1
average: 42.1 52.2 66.7 57.0 48.4 95.4
Predicted values correspond to molecular docking scores, observed values are from enzymatic assays at 2 mM compound concentration, n.m. – not measured.
doi:10.1371/journal.pone.0010969.t002
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and still cannot be applied to practical tasks without in vitro and in
vivo validation. Nevertheless, the method was able to confirm the
choice of one of the two universal inhibitors and was able to select
the most specific human 17b-HSD 1 inhibitor based on docking
results on human 17b-HSD homologs, despite generally quite low
correlation between the docking scores and observed inhibition.
However, at present molecular modeling experiments done on
modeled enzyme structures should be interpreted with caution.
Closing Remarks
In this work we contributed to the field of inhibitor development
in estrogen metabolism by 17b-HSD 1 by the quantification of
inhibitor preferences between human and animal models used in
the process of drug screening. Based on our data, steroid
metabolism inhibitor development should be validated rather
with primates or pig than with rodents. Otherwise, good candidate
compounds against human targets would be already out-selected
by experiments in the rodent model during pre-clinical optimiza-
tion steps although they might have been specific and valuable
drugs in disease treatment in humans.
Materials and Methods
Compound Synthesis
Compounds were synthesized as described elsewhere [24],
compound 5 developed by Sterix (Ipsen SA) was re-synthesized
according to [35]. Structures of compounds used for testing are
given in Figure 1.
Expression of Recombinant Enzymes in E.coli
Full length cDNAs of several 17b-HSDs type 1 originating from
different species were cloned either into the pQE30 vector (human
17b-HSD 1, coding for acc. no. NP_000404) for expression as
His-Tag protein or into a modified pGex-2T vector [63] (mouse
17b-HSD 1, acc. no. NP_034605; rat 17b-HSD 1, acc.
no. NP_036983; marmoset 17b-HSD 1, acc. no. AAG01115;
porcine 17b-HSD 1, acc. no. NP_001121944) for expression as
GST-fusion proteins. The marmoset 17b-HSD 1 enzyme
sequence was updated by the missing N-terminal part
(AF272013) and the new porcine sequence was submitted to
GenBank (NP_001121944). Human 17b-HSDs 2, 4, 5 (AKR1C3,
the latter kindly provided by Dr. T. Penning) and 7 were all cloned
into the modified pGEX-2T vector. For 17b-HSD 4 only the
SDR-domain converting the steroids was subcloned [63]. Plasmids
were transformed into E.coli BL21 DE3 Codon Plus RP
(Stratagene) and enzyme expression was induced by 0.5 mM
IPTG. After 4h incubation at 37uC with continuous shaking
bacteria were pelleted by centrifugation at 10.0006g. Pellets were
stored until use at 220uC.
Enzyme Identities
Recently, the international SDR-Initiative has recommended
[8] a new nomenclature for the human enzymes analyzed in this
study. Here we provide for referencing purposes traditional and
new names: 17b-HSD 1 – SDR28C1, 17b-HSD 2 – SDR9C2,
17b-HSD 4 – SDR8C1, 17b-HSD 5 – AKR1C3, 17b-HSD 7 –
SDR37C1.
In Vitro Measurement of Enzymatic Activity
Catalytic activity towards estrone and estradiol was assessed as
originally described [25,64] with minor modifications. The
bacteria containing recombinant enzymes were resuspended in
PBS and enzymatic assays were performed in 100 mM sodium
phosphate buffer at pH 6.6 for the reductive reaction and at
pH 7.7 for the oxidative reaction. The concentration of
3H-
labelled steroid substrates in the reaction mixtures were 15 nM for
estrone (2,4,6,7-
3H(N)) in assays of 17b-HSD 1 and 7), 21 nM for
estradiol (6,7-
3H(N)) in assays of 17b-HSD 2 and 4, and 21 nM for
androstenedione (1,2,6,7-
3H(N)) in assays for 17b-HSD 5. All
substrates were purchased from NEN/Perkin Elmer. The
Table 3. Comparison of predicted and observed inhibition for five compounds and four human 17b-HSD 1 homologs.
Predicted consensus score
17b-HSD type_speciesa
a Compound
1 2345
1_human 72.1 53.6 53.6 57.1 58.1
2_human 40.3 31.3 31.5 83.0 26.5
4_human 18.6 18.7 6.6 75.7 217.1
5_human 49.3 73.9 62.6 81.7 64.5
7_human 46.3 27.9 54.7 69.5 25.9
Observed % inhibition
17b-HSD type_species
a Compound
1 2345
1_human 63.6 94.7 97.9 95.8 100.0
2_human 24.3 16.7 18.6 20.3 23.2
4_human 7.2 0.1 2.1 5.5 5.6
5_human 21.6 33.9 29.3 93.5 50.6
7_human 23.6 27.1 29.0 25.8 0.0
Predicted values correspond to molecular docking scores, observed values are from enzymatic assays at 2 mM compound concentration.
atype of enzyme is separated by underscore from species description.
doi:10.1371/journal.pone.0010969.t003
Species-Dependent Inhibition
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+
(Serva, for oxidative reactions) were used at final concentrations of
0.5 mg/ml. Potential inhibitors (dissolved in DMSO) were added
in a final concentration of 2 mM or 0.005 mMt o5mM in case of
IC50 determination (1% DMSO final each). The incubation at
37uC was stopped with 0.21 M ascorbic acid in methanol:acetic
acid 99:1 (v:v) after the time needed to convert approximately 30%
of the substrate in a control assay with 1% DMSO, without
inhibitor candidates. Substrates and products were extracted from
the reaction mixture by SPE with Strata C18-E columns
(Phenomenex), eluted by methanol and separated by RP-HPLC
in a Beckman-Coulter system, using the column Luna 5 mm
C18(2), 12564.0 mm (Phenomenex). The solvent used was
acetonitrile:water (43:57, v:v) at a flow rate of 1 ml/min.
Radioactivity was detected by online-scintillation counting (Bert-
hold LB506D) after mixing with ReadyFlowIII (Beckman).
Conversion was calculated from integration of substrate and
product peaks. For calculation of inhibitory potential conversion of
control assay (assay without inhibitor) was set to 0% inhibition. All
assays were run in duplicates of two independent experiments and
mean values are reported. The IC50 values were determined by
the One Ligand Binding model of SigmaPlot kinetics module.
Molecular Docking
The docking experiments where performed on 9 protein
models, i.e. 17b-HSD 1 from human, marmoset, mouse, rat and
pig, and further 17b-HSD 2, 4, 5 and 7 from human. Amino acid
sequences were aligned with T-coffee [65] and inspected with
Boxshade 3.21 (http://www.ch.embnet.org/software/BOX_form.
html).
Models where based on the crystal structures deposited in the
Protein Data Bank. For the human enzymes 17beta-HSD type 1,
4, and 5 the PDB entries 1A27, 1ZBQ, and 2FGB, respectively,
were directly used [66,67,68,69]. If crystal structures were not
available, a homology modeling procedure based on aligning the
sequence of the target protein with the sequence of the closest
homolog deposited in PDB was applied. For 17beta-HSD1 of
other species and human 17b-HSD 2 the template 1A27 was used,
for 17b-HSD7 entry 1N5D served as template. C-terminal parts of
the proteins analyzed revealed lower similarities and were not
included in the model building. This local dissimilarity a typical
effect of SDR-protein family already approached by us in
modeling studies [70]. Models where generated automatically
using the MODELLER program (modbase.compbio.ucsf.edu/
ModWeb20-html/modweb.html).
Docking of compounds was performed using the following 7
docking programs: AutoDock, Cdocker, eHits, LigFit, Dock,
Surflex and Glide accessible as described [71]. From each
program one final score was selected as estimator of the fitness
function and predictor for the experimental inhibition.
The consensus scoring method was based on multivariate linear
regression analysis (least squares method) which assigns coefficients
to each of the 7 docking programs to maximize the fitness between
a linear combination of the 7 docking scores multiplied by the
coefficients (predicted values) and the observed experimental
inhibition (observed values). To eliminate the training (memori-
zation) effect a jackknife procedure was employed. The regression
analysis for a respective tested compound-protein pair was
conducted in this case by using only values obtained for other
compound-protein pairs (removing the tested pair from the
dataset).
Additionally, a modified consensus method was created that
used only scores and correlation coefficients of 2 docking programs
(AutoDock and eHits) performing best on our dataset (exhibiting
highest correlation between the predicted and observed values) by
setting the docking scores of 5 docking methods (Cdocker, LigFit,
Dock, Surflex, Glide) to 0.
The estimation of the accuracy of the docking protocol was
based on the Pearson correlation coefficient between the predicted
score and the observed inhibition. The estimation was conducted
also separately for each model and each compound. When
assessing the correlation for a protein model only compound-
protein pairs with this protein were left in the dataset. Likewise, the
correlation for a compound was calculated only on pairs with this
compound.
Gene Bank Submissions
The sequence of marmoset 17b-HSD was extended by the
missing N-terminal part (AF272013) and the porcine sequence
received acc. no NP_001121944.
Supporting Information
Table S1 Prediction results for inhibitors of different human
17b-HSD types in different species.
Found at: doi:10.1371/journal.pone.0010969.s001 (0.12 MB
DOC)
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